Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2009

View Archived Issues

Merck Frosst describes cysteine protease inhibitors for the treatment of parasitic infections

Novel histamine H3 receptor ligands revealed in recent Janssen patents

Wyeth discovers novel PDE10 inhibitors for the treatment of psychosis, mood disorders, etc.

Further phase II data on IMC-11F8 plus mFOLFOX-6 in advanced colorectal cancer reported

Medicago reports results from immunogenicity study in mice of its swine flu vaccine

CytRx files response to partial FDA clinical hold on phase IIb arimoclomol trial

Pregabalin effective in first controlled study in restless legs syndrome

Sucampo announces results from phase II trial of cobiprostone in patients treated with NSAIDs

Shire's Vyvanse demonstrates efficacy in a phase IIIb study in adults with ADHD

Bionomics updates clinical progress of BNC-105 and BCN-210

Graceway acquires early-stage dermatological compounds from Pfizer

Cardioxyl commences phase I/IIa study for CXL-1020 in heart failure

FDA issues complete response letter regarding Acura's and King's NDA for Acurox

Oncolytics completes enrollment in phase I/II trial of Reolysin in head and neck cancer

Johnson & Johnson acquires Elan's Alzheimer's immunotherapy program

Myriad Pharmaceuticals completes spin-off from Myriad Genetics

Eisai updates Aricept's development programs of new indications and formulations

Asthmatic responses reduced with eculizumab in allergic asthmatics

TRPA1 antagonist HC-030031 alleviates experimental allergic asthma

Phase III data show significant effects of DX-88 on hereditary angioedema attacks

Tekmira initiates phase I human clinical trial of ApoB SNALP for LDL cholesterol

European Commission grants marketing authorization for Novo Nordisk's Victoza

FDA grants approval to Clavis to include U.S. patients in phase II clinical trial of CP-4126

Rosiglitazone combination therapy increases the risk of heart failure but not CV mortality

Lundbeck reports results from dose-finding clinical trial of Lu-AA-24530 in MDD